Preparation, characterization and pharmacokinetic studies of total paeony glycoside nanocrystals

doi:10.5246/jcps.2018.02.011

Abstract

Abstract:

Total paeony glycoside (TPG) is obtained from Radix Paeoniae Rubra with a variety of bioactivities. However, the low solubility and bioavailability limit its application. The present study aimed to develop TPG nanocrystals to increase the dissolution and then improve the oral bioavailability. TPG nanocrystals were prepared via precipitation and high-pressure homogenization method. The physical-chemical properties of the optimal TPG nanocrystals in terms of particle size, zeta potential, morphology and crystallinity were evaluated. The results showed that TPG nanocrystals had a mean particle size of (210.2±2.5) nm, a polydispersity index of 0.191±0.033 and a zeta potential of (–22.4±1.2) mV. The result of differential scanning calorimetry showed that the nanocrystals were still in crystalline state after the preparation procedure. Transmission electron microscopy (TEM) results showed that the nanosuspension was in spherical shape. The pharmacokinetics of TPG nanocrystals for rats was investigated by liquid chromatography-tandem mass spectroscopy (LC-MS/MS). Compared with the TPG coarse suspension, TPG nanocrystals exhibited significant increase in AUC_0–∞ (approximately 1.85-fold). Taken together, TPG nanocrystals could be used as a promising drug delivery system due to the enhanced oral bioavailability of TPG.

Key words: Total paeony glycoside, Nanocrystals, High-pressure homogenization, Pharmacokinetics, Bioavailability

CLC Number:

R969.1

Supporting:

Jinfeng Zhang, Fan Wu, Jiayi Han, Jinghong Rong, Yi Li, Yu Liu, Xiao Liang, Xin Wang, Hao Pan, Hongsheng Liu, Lijiang Chen. Preparation, characterization and pharmacokinetic studies of total paeony glycoside nanocrystals[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(2): 99-108.

References

[1] Zhang, W.; Dai S.M. Mechanisms Involved in the Therapeutic Effects of Paeonia Lactiflora Pallas in Rheumatoid Arthritis. Int. Immunopharmacol. 2012, 14, 27-31.

[2] Lan, R.J.; Xiang, Z.Z.; Zhong, Z.Q. Recent Advances in Study of Components and Pharmacological Roles of Radix Paeoniae Rubra. Chin. Pharmacol. Bull. 2003, 9, 965-970.

[3] Xu, H.Y.; Chen, Z.W.; Wu, Y.M. Antitumor Activity of Total Paeony Glycoside against Human Chronic Myelocytic Leukemia K562 Cell Lines In Vitro and In Vivo. Med. Oncol. 2012, 29, 1137-1147.

[4] Wang, Y.; Chen, M.; Xu, S. Analgesic Effect of Total Glucosides of Paeonia Lactiflora. Chin. J. Pharmacol. Toxicol. 1988, 2, 6-10.

[5] Xu, W.; Zhong, W.; Liu, J.; Liu, H.; Zhu, B. Study on Anti-Tumor Effect of Total Glycosices from Radix Paeoniae Rubra in S180 Tumor-Bearing Mice. Afr. J. Tradit. Complement Altern. Med. 2013, 10, 580-585.

[6] Long, J.; Gao, M.; Kong, Y.; Shen, X.; Du, X.; Son, Y.O.; Shi, X.; Liu, J.; Mo, X. Cardioprotective Effect of Total Paeony Glycosides against Isoprenaline-Induced Myocardial Ischemia in Rats. Phytomedicine. 2012, 19, 672-676.

[7] Luo, C.; Wang, H.; Chen, X.; Cui, Y.; Long, J.; Mo, X.; Liu, J. Protection of H9c2 Rat Cardiomyoblasts against Oxidative Insults by Total Paeony Glucosies from Radix Paeoniae Rubrae. Phytomedicine. 2013, 21, 20-24.

[8] Ou-Yang, Y. Research of Alcohol Extract of Paeonia Lactiflora Pall in Anti-Inflammatory and Analgesic Effect. J. Math. Med. 2008, 21, 600-602.

[9] Xu, X.X.; Qi, X.M.; Zhang, W.; Zhang, C.Q.; Wu, X.X.; Wu, Y.G.; Wang, K.; Shen, J.J. Effects of Total Glucosides of Paeony on Immune Regulatory Toll-Like Receptors TLR2 and 4 in the Kidney from Diabetic Rats. Phytomedicine. 2014, 21, 815-823.

[10] Li, R.; Guo, W.; Fu, Z.; Ding, G.; Zou, Y.; Wang, Z. Hepatoprotective Action of Radix Paeoniae Rubra Aqueous Extract against CCl4-Induced Hepatic Damage. Molecules. 2011, 16, 8684-8694.

[11] Dou, Z.H., Luo, L.; Lu, D. Purification of Total Paeony Glycoside by Macroporous Resin with Double Indices of Albiflorin and Paeoniflorin. J. Chin. Med. Mater. 2009, 8, 1282-1284.

[12] Müller, R.H.; Jacobs, C.; Kayser, O. Nanosuspensions As Particulate Drug Formulations in Therapy: Rationale for Development and What We Can Expect for the Future. Adv. Drug Deliv.Rev. 2001, 47, 3-19.

[13] Scholz, P.; Keck, C.M. Nanocrystals: From Raw Material to the Final Formulated Oral Dosage Form-A Review. Curr. Pharm. Des. 2015, 21, 4217-4228.

[14] Keck, C.M.; Müller, R.H. Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Homogenization. Eur. J. Pharm. Biopharm. 2006, 62, 3-16.

[15] Böhm, B.H.; Müller, R.H. Lab-Scale Production Unit Design for Nanosuspensions of Sparingly Soluble Cytotoxic Drugs. Pharm. Sci. Technolo. Today. 1999, 2, 336-339.

[16] Kesisoglou, F.; Panmai, S.; Wu, Y. Nanosizing—Oral Formulation Development and Biopharmaceutical Evaluation. Adv. Drug Deliv. Rev. 2007, 59, 631-644.

[17] Müller, R.H.; Gohla, S.; Keck, C.M. State of the Art of Nanocrystals-Special Features, Production, Nanotoxicology Aspects and Intracellular Delivery. Eur. J. Pharm. Biopharm. 2011, 78, 1-9.

[18] Zhang, Y.; Zhan, Y.; Pang, N.; Liu, Y.; Cheng, S.; Li, J.; Du, Y.; Qi, X. Preparation, Characterization and Pharma-cokinetics of 10-Hydroxycamptothecin Nanosuspension. J. Chin. Pharm. Sci. 2017, 26, 574-581.

[19] Liu, C.Z.; Chang, J.H.; Zhang, L.; Xue, H.F.; Liu, X.G.; Liu, P.; Fu, Q. Preparation and Evaluation of Diosgenin Nanocrystals to Improve Oral Bioavailability. AAPS PharmSciTech. 2016, 1-10.

[20] Liu, Y.; Xie, P.; Zhang, D.; Zhang, Q.A. Mini Review of Nanosuspensions Development. J. Drug Target. 2012, 20, 209-223.

[21] Wang, Y.; Liu, Z.; Zhang, D.; Gao, X.; Zhang, X.; Duan, C.; Jia, L.; Feng, F.; Huang, Y.; Shen, Y.; Zhang, Q. Development and In Vitro Evaluation of Deacety Mycoepoxydiene Nanosuspension. Colloids Surf. B. 2011, 83, 189-197.

[22] Li, L.; Liu, Y.; Wang, J.; Chen, L.; Zhang, W.; Yan, X. Preparation, In Vitro and In Vivo Evaluation of Bexarotene Nanocrystals with Surface Modification by Folate-Chitosan Conjugates. Drug Deliv. 2014, 1-9.

[23] Fu, Q.; Ma, M.; Li, M.; Wang, G.; Guo, M.; Li, J.; Hou, Y.; Fang, M. Improvement of Oral Bioavailability for Nisoldipine Using Nanocrystals. Powder Technol. 2017, 305, 757-763.

[24] Gao, L.; Liu, G.; Ma, J.; Wang, X.; Zhou, L.; Li, X. Drug Nanocrystals: In Vivo Performances. J. Controlled Release. 2012, 160, 418-430.